A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib's Journey from Discovery to Approval and What's Next in CDK Inhibition in Breast Cancer.
Saved in:
| Title: | A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib's Journey from Discovery to Approval and What's Next in CDK Inhibition in Breast Cancer. |
|---|---|
| Authors: | Finn RS; Division of Hematology/Oncology, David Geffen School of Medicine, University of California Los Angeles, 885 Tiverton Drive, Los Angeles, CA, 90095, USA., Rugo HS; City of Hope, Duarte Cancer Center, Duarte, CA, USA., Cortes J; International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain.; IOB Madrid, Institute of Oncology, Hospital Beata Maria Ana, Madrid, Spain., Loibl S; Center for Hematology and Oncology Bethanien, Frankfurt, Germany., Foley G; Pfizer Ltd, Surrey, UK., Gauthier E; Pfizer Inc, San Francisco, CA, USA., Wang Y; Pfizer Inc, New York, NY, USA., Kim S; Pfizer Inc, San Diego, CA, USA., Anders L; Pfizer Inc, San Diego, CA, USA., Slamon DJ; Division of Hematology/Oncology, David Geffen School of Medicine, University of California Los Angeles, 885 Tiverton Drive, Los Angeles, CA, 90095, USA. dslamon@mednet.ucla.edu. |
| Source: | Targeted oncology [Target Oncol] 2025 Nov; Vol. 20 (6), pp. 917-936. Date of Electronic Publication: 2025 Oct 14. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1776-260X |
|---|---|
| DOI: | 10.1007/s11523-025-01175-z |
